Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Digestive Disorder

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1480640

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1480640

Short Bowel Syndrome (SBS)

PUBLISHED:
PAGES: 194 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 14850

Add to Cart

Description

Table of Contents

Global Short Bowel Syndrome (SBS) Market to Reach $5.7 Billion by 2030

The global market for Short Bowel Syndrome (SBS) estimated at US$1.4 Billion in the year 2023, is expected to reach US$5.7 Billion by 2030, growing at a CAGR of 21.6% over the analysis period 2023-2030. GLP-2 Drug Class, one of the segments analyzed in the report, is expected to record a 23.2% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Growth Hormone Drug Class segment is estimated at 20.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $444.6 Million, While China is Forecast to Grow at 20.2% CAGR

The Short Bowel Syndrome (SBS) market in the U.S. is estimated at US$444.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$934.2 Million by the year 2030 trailing a CAGR of 20.2% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 19.2% and 17.8% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 14.5% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 42 Featured) -

  • Ardelyx, Inc.
  • Emmaus Life Sciences, Inc.
  • Merck KgaA
  • Naia Pharmaceuticals Inc.
  • Nutrien Ltd.
  • OxThera AB
  • Shire PLC
  • Zealand Pharma A/S
Show more
Product Code: MCP14715

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Short Bowel Syndrome (SBS) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Short Bowel Syndrome (SBS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Short Bowel Syndrome (SBS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for GLP-2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for GLP-2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for GLP-2 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Growth Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Growth Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Growth Hormone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Glutamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Glutamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Glutamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Short Bowel Syndrome (SBS) Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
  • JAPAN
    • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
  • CHINA
    • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
  • EUROPE
    • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Short Bowel Syndrome (SBS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
  • FRANCE
    • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
  • GERMANY
    • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!